Your browser doesn't support javascript.
loading
Heart transplantation in Fontan patients across Australia and New Zealand.
Shi, William Y; Yong, Matthew S; McGiffin, David C; Jain, Pankaj; Ruygrok, Peter N; Marasco, Silvana F; Finucane, Kirsten; Keogh, Anne; d'Udekem, Yves; Weintraub, Robert G; Konstantinov, Igor E.
Afiliação
  • Shi WY; Departments of Cardiac Surgery and Cardiology, Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.
  • Yong MS; Department of Cardiothoracic Surgery, The Alfred Hospital, Monash University, Melbourne, Australia.
  • McGiffin DC; Department of Cardiothoracic Surgery, The Alfred Hospital, Monash University, Melbourne, Australia.
  • Jain P; Department of Cardiology, St Vincent's Hospital, Sydney, Australia.
  • Ruygrok PN; Greenlane Cardiothoracic Unit, Auckland City Hospital, Auckland, New Zealand.
  • Marasco SF; Department of Cardiothoracic Surgery, The Alfred Hospital, Monash University, Melbourne, Australia.
  • Finucane K; Greenlane Cardiothoracic Unit, Auckland City Hospital, Auckland, New Zealand.
  • Keogh A; Department of Cardiology, St Vincent's Hospital, Sydney, Australia.
  • d'Udekem Y; Departments of Cardiac Surgery and Cardiology, Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.
  • Weintraub RG; Departments of Cardiac Surgery and Cardiology, Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.
  • Konstantinov IE; Departments of Cardiac Surgery and Cardiology, Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.
Heart ; 102(14): 1120-6, 2016 07 15.
Article em En | MEDLINE | ID: mdl-27000055
OBJECTIVE: Patients with Fontan physiology may eventually require heart transplantation (HT). We determined the rates and outcomes of HT in a national, population-based multicentre study. METHODS: From 1990 to 2015, 1369 patients underwent the Fontan procedure as recorded in the Australia and New Zealand Fontan Registry. We identified those who underwent HT and analysed their outcomes. We compared rates of HT between two catchment areas. In area 1 (n=721), patients were referred to the national paediatric HT programme or its associated adult programme. In area 2 (n=648), patients were referred to the national paediatric HT programme or one of the other adult HT programmes. RESULTS: Mean follow-up time post-Fontan was 11±8 years. Freedom from Fontan failure was 74%±3.9% at 20 years. HT was performed in 34 patients. Patients living in area 1 were more likely to have HT (4.0%, 29/721 vs 0.8%, 5/648, p<0.001) with a cumulative proportion of 3.4% vs 0.7% at 10 years and 6.8% vs 1.2% at 20 years (p=0.002). Area 1 patients were more likely to undergo HT (hazard ratio 4.7, 95% CI 1.7 to 13.5, p=0.003) on multivariable regression. Post-HT survival at 1, 5 and 10 years was 91%, 78% and 71%, respectively. Compared with other patients with congenital heart disease (n=87), Fontan patients had similar in-hospital outcomes and long-term survival. CONCLUSIONS: Although HT after the Fontan procedure can be achieved with excellent outcomes, most patients with Fontan failure do not undergo HT. Significant regional differences in rates of HT in Fontan patients exist.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Transplante de Coração / Técnica de Fontan / Disparidades em Assistência à Saúde / Cardiopatias Congênitas Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Transplante de Coração / Técnica de Fontan / Disparidades em Assistência à Saúde / Cardiopatias Congênitas Idioma: En Ano de publicação: 2016 Tipo de documento: Article